Avior is a clinical stage, pharmaceutical company developing drugs for distressed neurological conditions. The firm's disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – positions the firm to develop products that bring value both in terms of efficacy and in safety. Avior's lead product – AV104 – is designed to address treatment of Prurigo Nodularis and chronic kidney disease associated pruritus. In 2019, in response to the US Opioid crisis, and with NIH support, principals of the firm added a second product – AV103 – designed to create a medical counter measure (MCM) for the reversal of opioid induced respiratory
